2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Myelodysplastic Syndromes
5
Recurrence
4
Leukemia, Myeloid, Acute
3
Leukemia
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Lung Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rubinstein-Taybi Syndrome
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Leukemia, Lymphoid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Carcinoma, Transitional Cell
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
mocetinostat
×
Clear all
NCT02993991
2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1
Withdrawn